Saturday 17 October 2026 Export ATRC’s income statement to Excel — free account

AtriCure, Inc.

ATRC Healthcare Medical Instruments & Supplies

AtriCure, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $534.5 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 12.8%, EPS grew 238.5%, free cash flow fell 2.79% and total debt fell 4.43%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

56.09 1.69 −2.92%

Follow ATRC

Alert me

Market cap: $2.9B
P/E: 259×
Fwd P/E: 591×
Dividend yield: —
F-score: 7/9
Altman Z: 7.31
Beneish M: −2.91
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 4.37

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	3	—	—	—	1	—	2	—	3	3	4	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2,940.00

Revenue 569.62

Net Income 10.55

Free Cash Flow 53.11

Net Debt (96.74)

Current Ratio 4.22

Debt/Equity 0.14

P/E ratio 258.96

Fwd P/E 591.00

P/S ratio 4.79

P/B ratio 5.29

Past 5Y EPS Growth —

This Y EPS Growth 145.15%

Next Y EPS Growth 288.17%

Next Y revenue growth 13.43%

Next 5Y EPS Growth 62.27%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 52.41%

10-year low 10-year high

P/B against its own 10 years 77.07%

10-year low 10-year high

EV/Sales against its own 10 years 52.45%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	137	123	167	168
Receivables	53	60	67	80
Inventory	68	75	78	84
Other	—	—	—	—
	266	268	323	346

	2023	2024	2025	Q'26
Payables	27	25	25	36
ST’ Debt	—	—	—	—
Other	—	3	3	3
	75	73	82	82

Compound Annual Growth %

	10y	5y	3y
Sales	15.21%	20.95%	17.40%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	10.17%	3.59%	2.50%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	141	154	—	—	—
’25	124	136	134	141	535
’24	109	116	116	124	465
’23	93	101	98	107	399
’22	75	85	83	88	330
’21	59	71	70	73	274
’20	53	41	55	58	207

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	22	—	—	—
’25	(11)	22	27	20	57
’24	(21)	7	20	6	12
’23	(4)	3	2	4	4
’22	(25)	4	(2)	0	(22)
’21	(9)	(5)	0	0	(14)
’20	(16)	(12)	4	4	(20)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	18	—	—	—
’25	(13)	19	24	18	48
’24	(24)	5	16	3	1
’23	(7)	(30)	(2)	1	(8)
’22	(28)	0	(7)	(4)	(39)
’21	(11)	(9)	(2)	(2)	(24)
’20	(18)	(13)	3	3	(25)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.00	0.18	—	—	—
’25	(0.14)	(0.13)	(0.01)	0.04	(0.24)
’24	(0.28)	(0.17)	(0.17)	(0.33)	(0.95)
’23	(0.14)	(0.11)	(0.20)	(0.21)	(0.66)
’22	(0.33)	(0.32)	(0.27)	(0.09)	(1.02)
’21	(0.38)	(0.36)	2.11	(0.30)	1.09
’20	(0.42)	(0.20)	(0.11)	(0.42)	(1.14)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	13.44	14.78	14.88	22.57	23.17	52.54	32.51	32.27	18.94	28.29	Analyst estimates 2026–2028 Powerpack
	High	22.42	25.18	36.49	33.92	58.03	89.18	72.31	59.61	39.05	43.11
People
People	Employees	500	570	620	730	750	875	1,050	1,200	1,300	330
	Revenue/emp, $m	0.31	0.31	0.33	0.32	0.28	0.31	0.31	0.33	0.36	1.62
Income, $m
Income, $m	Revenue	155	175	202	231	207	274	330	399	465	535
	Gross margin, %	71.63	72.21	72.97	73.80	72.29	75.04	74.44	75.23	74.69	74.98
	EBT	(33)	(27)	(21)	(35)	(48)	50	(46)	(30)	(44)	(10)
	EBT margin, %	(21.47)	(15.38)	(10.37)	(15.16)	(23.26)	18.37	(13.98)	(7.48)	(9.39)	(1.90)
	Net income	(33)	(27)	(21)	(35)	(48)	50	(46)	(30)	(45)	(11)
	Depreciation	10	9	9	9	11	96	14	16	19	21
Per share, $
Per share, $	Revenue	4.91	5.39	5.92	6.14	4.90	6.09	7.22	8.62	9.91	11.19
	Earnings	(1.05)	(0.83)	(0.62)	(0.94)	(1.14)	1.11	(1.02)	(0.66)	(0.95)	(0.24)
	Cash flow	(0.48)	(0.28)	(0.12)	(0.42)	(0.47)	(0.31)	(0.48)	0.10	0.26	1.20
	Capex	(0.24)	(0.20)	(0.18)	(0.32)	(0.12)	(0.22)	(0.37)	(0.26)	(0.24)	(0.19)
	Free cash flow	(0.72)	(0.47)	(0.30)	(0.74)	(0.60)	(0.52)	(0.85)	(0.16)	0.02	1.01
	Book value	5.33	4.98	7.32	6.58	9.79	10.73	9.99	10.07	9.82	10.30
	Shares, m	32	32	34	38	42	45	46	46	47	48
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	62.64	0.00	0.00	0.00	0.00
	P/S	3.91	3.42	5.17	5.29	11.35	11.42	6.21	4.10	3.08	3.53
	P/B	3.60	3.71	4.18	4.94	5.69	6.48	4.49	3.51	3.11	3.84
	EV/Sales	3.89	3.45	4.81	5.26	10.49	11.25	6.06	3.96	3.00	3.40
	EV/FCF	(26.42)	(39.35)	(93.38)	(43.42)	(86.24)	(131.13)	(51.29)	(42.11)	(47.73)	99.30
Cash, $m
Cash, $m	Operating cash flow	(15)	(9)	(4)	(16)	(20)	(14)	(22)	4	12	57
	Capex	(8)	(6)	(6)	(12)	(5)	(10)	(17)	(12)	(11)	(9)
	Free cash flow	(23)	(15)	(10)	(28)	(25)	(24)	(39)	(8)	1	48
Balance, $m
Balance, $m	Working capital	57	50	134	93	258	140	157	192	194	241
	Total debt	39	37	52	74	66	72	71	61	62	62
	Net debt	(5)	3	(72)	(8)	(178)	(48)	(50)	(77)	(61)	(106)
	Shareholders’ equity	168	161	249	247	412	484	457	466	461	492
Returns, %
Returns, %	ROA	(12.13)	(9.88)	(6.77)	(7.70)	(7.57)	7.55	(7.74)	(5.08)	(7.31)	(1.81)
	ROIC	(11.92)	(9.51)	(6.03)	(8.66)	(11.80)	7.91	(6.55)	(4.28)	(6.25)	(1.53)
	ROE	(18.78)	(16.32)	(10.30)	(14.17)	(14.60)	11.20	(9.88)	(6.60)	(9.64)	(2.40)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
STVN Stevanato Group S.p.A.	$5.3B	33.8×	27.5×	+10.46% (above 0%: growing)	−25.00% (below 0%: shrinking)	−167.02% (below 0%: shrinking)	28.75%	12.93%	Compare
ICUI ICU Medical, Inc.	$4.2B	136×	49.5×	+0.51% (above 0%: growing)	−46.85% (below 0%: shrinking)	+655.98% (above 0%: growing)	42.61%	7.09%	Compare
NVST Envista Holdings Corporation	$3.8B	38.8×	24.4×	+7.10% (above 0%: growing)	+106.25% (above 0%: growing)	+37.57% (above 0%: growing)	55.72%	10.99%	Compare
PLSE Pulse Biosciences, Inc	$3.3B	— (loss-making)	— (loss-making)	+4,922.22% (above 0%: growing)	n/m	−45.39% (below 0%: shrinking)	37.10%	(5,823.04%)	Compare
WRBY Warby Parker Inc.	$3.0B	334×	122×	+9.81% (above 0%: growing)	n/m	−71.75% (below 0%: shrinking)	57.94%	1.34%	Compare
ATRC AtriCure, Inc.	$2.9B	259×	591×	+12.83% (above 0%: growing)	n/m	−2.79% (below 0%: shrinking)	77.23%	6.29%
LMAT LeMaitre Vascular, Inc.	$1.9B	27.9×	31.5×	+9.57% (above 0%: growing)	+22.95% (above 0%: growing)	−27.95% (below 0%: shrinking)	72.13%	28.98%	Compare
XRAY DENTSPLY SIRONA Inc.	$1.8B	— (loss-making)	27.0×	−4.06% (below 0%: shrinking)	n/m	+252.94% (above 0%: growing)	54.90%	9.13%	Compare
KMTS Kestra Medical Technologies, Ltd.	$1.7B	— (loss-making)	— (loss-making)	+59.88% (above 0%: growing)	n/m	−17.75% (below 0%: shrinking)	56.50%	(121.59%)	Compare
Median of peers	$3.2B	38.8×	29.5×	+9.69%	−1.02%	−22.85%	55.31%	8.11%

All 55 Medical Instruments & Supplies stocks →

AtriCure, Inc. (ATRC) key facts

Strength: AtriCure, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $534.5 million, up 14.9% from fiscal 2024.
AtriCure, Inc. (ATRC) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ATRC traded at $56.09, a market capitalization of $2.9 billion.
Return on equity was −2.40% and debt-to-equity 0.14.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 7.31 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.